What is the best treatment approach for a 73-year-old man with locally advanced (stage III) prostate cancer, Gleason 3 + 4, and comorbid diabetes and hypertension?

Treatment Approach for Stage III Prostate Cancer in a 73-Year-Old

For this 73-year-old man with locally advanced (stage III) prostate cancer, Gleason 3+4, the optimal treatment is external beam radiotherapy (EBRT) combined with androgen deprivation therapy (ADT) plus abiraterone and prednisolone for 2 years, with ADT continued for a total of 3 years. 1

Primary Treatment Strategy

The 2021 ASCO guidelines provide the strongest evidence for this clinical scenario. ADT plus abiraterone and prednisolone should be considered for men with noncastrate locally advanced nonmetastatic prostate cancer, rather than castration monotherapy, because of the failure-free survival benefit demonstrated in the STAMPEDE trial 1. This represents high-quality evidence with a strong recommendation.

Radiation Therapy Component

For the radiation component, deliver intensity-modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT) with image-guided radiotherapy (IGRT) at:

• Total dose of 76-78 Gy using conventional fractionation, OR
• Moderate hypofractionation: 60 Gy in 20 fractions over 4 weeks or 70 Gy in 28 fractions over 6 weeks 2

Radiotherapy to the primary prostate was mandated in STAMPEDE for patients with newly diagnosed node-negative, nonmetastatic disease 1.

Hormonal Therapy Regimen

The hormonal therapy should consist of:

1. Neoadjuvant and concurrent ADT for 4-6 months (started before and continued during radiation) 3
2. Abiraterone acetate plus prednisolone for 2 years total 1
3. ADT continued for 2-3 years total 3

This combination significantly improved failure-free survival (time to biochemical failure, disease progression, or death) compared to ADT alone 1.

Comorbidity Considerations

Managing Diabetes and Hypertension

Given this patient's diabetes and hypertension, several important considerations apply:

Diabetes management: The diabetes itself may actually have a protective effect on prostate cancer risk 4, but metabolic control remains important. Monitor glucose closely as ADT can worsen insulin resistance.

Hypertension management: This requires particular attention because:

• ADT itself can increase cardiovascular risk and potentially worsen hypertension 5
• Abiraterone specifically can cause hypertension as a side effect
• Target blood pressure should be 130/80 mmHg, balanced against risks of orthostatic symptoms and falls in this elderly patient 5
• Preference should be given to ACE inhibitors or ARBs (RAS inhibitors), which may have protective effects in prostate cancer 6
• Avoid calcium channel blockers if possible, as they may be associated with increased prostate cancer risk 6

Age-Specific Considerations

At age 73, this patient should be assessed for fitness rather than excluded based on chronological age alone 7, 8, 9. Evaluate:

• Functional status: Activities of daily living (ADL) and instrumental ADL
• Comorbidity burden: Using tools like Cumulative Illness Scoring Rating-Geriatrics
• Nutritional status: Screen for malnutrition

If the patient is "fit" (no ADL impairment, controlled comorbidities, adequate nutrition), he should receive standard treatment as outlined above 8, 9. His diabetes and hypertension, if well-controlled, should not preclude standard therapy.

Alternative Approach (Resource-Constrained Settings)

If abiraterone is not available or affordable, combined androgen blockade using ADT plus a first-generation antiandrogen (bicalutamide, flutamide, or nilutamide) may be offered with radiotherapy, though this is a moderate rather than strong recommendation 1.

Critical Monitoring During Treatment

Prevent gynecomastia: Administer breast irradiation (8-15 Gy in 1-3 fractions) 1-2 weeks before initiating antiandrogen therapy 10.

Monitor for ADT side effects:

• Encourage regular exercise to reduce fatigue and improve quality of life 3
• Monitor bone health and consider bisphosphonates
• Watch for metabolic syndrome worsening
• Assess cardiovascular risk regularly

Blood pressure monitoring: Check BP at each visit, adjusting antihypertensive medications proactively when starting abiraterone.

What NOT to Do

Do not offer radical prostatectomy as primary treatment for stage III disease in this age group with comorbidities. While surgery plus pelvic lymphadenectomy is an option for high-risk/locally advanced disease 3, the combination of age, comorbidities, and locally advanced stage makes radiotherapy plus hormonal therapy the superior choice.

Do not use ADT alone without radiotherapy or intensification with abiraterone, as this provides inferior outcomes 1, 3.

Do not consider watchful waiting or active surveillance for stage III disease—these are only appropriate for low-risk disease 3, 2.